Dose of intravitreal bevacizumab (avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy

Retina

Volumn 30, Issue 5, 2010, Pages 761-764

  Hattori, Takayuki ^a   Shimada, Hiroyuki ^a   Nakashizuka, Hiroyuki ^a   Mizutani, Yoshihiro ^a   Mori, Ryusaburo ^a   Yuzawa, Mitsuko ^a  

^a NIHON UNIVERSITY   (Japan)

Author keywords

25 gauge vitrectomy; Avastin; Bevacizumab; Coagulation spots; Intraoperative bleeding; Lower dose; Preoperative adjunct therapy; Proliferative diabetic retinopathy; Standard dose; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG DOSE COMPARISON; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOSTASIS; HUMAN; INTRAOPERATIVE PERIOD; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PREOPERATIVE TREATMENT; SINGLE DRUG DOSE; VITRECTOMY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHEMOTHERAPY, ADJUVANT; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INJECTIONS; MIDDLE AGED; PREOPERATIVE CARE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY; VITREOUS BODY;

EID: 77952257913     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181c70168     Document Type: Article

References (16)

1. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695.e1-1695.e15.
2. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26:275-278.
3. Arevalo JF, Maia M, Flynn HW Jr, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008;92:213-216.
4. Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 2008;246:837-842.
5. da R Lucena D, Ribeiro JA, Costa RA, et al. Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study). Br J Ophthalmol 2009;93:688-691.
6. Oshima Y, Shima C, Wakabayashi T, et al. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology 2009;116:927-938.
7. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-859.
8. Bakri SJ, Cameron JD, McCannel CA, Pulido JS, Marler RJ. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 2006;142:162-164.
9. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006;26:257-261.
10. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006;26:262-269.
11. Feiner L, Barr EE, Shui YB, Holekamp NM, Brantley MA Jr. Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina 2006;26:882-888.
12. Inan UU, Avci B, Kusbeci T, Avci R, Temel SG. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 2007;48:1773-1781.
13. Peters S, Heiduschka P, Julien S, et al. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007;143:995-1002.
14. Shimomura Y, Hirata A, Ishikawa S, Okinami S. Changes in choriocapillaris fenestration of rat eyes after intravitreal bevacizumab injection. Graefes Arch Clin Exp Ophthalmol 2009;247:1089-1094.
15. Chen E, Hsu J, Park CH. Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema. Ophthalmic Surg Lasers Imaging 2009;40:68-70.
16. von Hanno T, Kinge B, Fossen K. Retinal artery occlusion following intravitreal anti-VEGF therapy. Acta Ophthalmol 2009 [Epub ahead of print].